Recent advances in ovarian cancer management include the demonstration of improved progression-free and overall survival with intraperitoneal (IP) chemotherapy in the adjuvant setting. For example, the Gynecologic Oncology Group (GOG) has reported an increase by 15.9 months in IP vs standard dose intravenous (IV) chemotherapy for good performance status in stage III patients after debulking. However, the added months come at significant impingement in quality of life, as apparent in the GOG trial and detailed in this report.Source:
Wenzel LB, et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2007;25:437-443.